FIND and Unitaid are supporting 21 in-country advocacy partners across 19 low- and middle-income countries to develop and implement advocacy strategies that will improve uptake of test-and-treat approaches to combat COVID-19
FIND, the global alliance for diagnostics and Unitaid are investing US$2 million in a coordinated advocacy programme spanning 19 low and middle income countries (LMICs) designed to boost access and uptake of COVID-19 tests and treatments. A total of 21 organisations have been selected from more than 300 applicants, following a request for proposals (RFP) and competitive selection process that included assessment by a panel of independent reviewers. Criteria for funding included previous public health advocacy experience and expected impact of test-and-treat advocacy in the targeted region.
FIND co-leads the Access to COVID-19 Tools (ACT) Accelerator Diagnostics Pillar, while Unitaid co-leads the Therapeutics Pillar. The Diagnostics Pillar’s Country Support Working Group, led by UNICEF, includes an Advocacy, Communications and Community Engagement (ACCE) Task Force (co-led by CHAI and UNICEF), which supports test-and-treat advocacy. This initiative follows the independent ACT-Accelerator strategic review that was published in October 2021, as well as calls from civil society, which both highlighted the need for increased inclusion and meaningful engagement of LMICs, regional bodies, civil society organizations, and community representatives in the COVID-19 response. Funded activities will provide avenues for stronger involvement of these key stakeholder groups in COVID-19 test-and-treat approaches.
Projects range in duration from 6 to 18 months, and will raise awareness of COVID-19 testing and treatment among the public, key opinion leaders, and specific high-risk and vulnerable groups.
Bill Rodriguez, CEO, FIND said, “We have the tools to defeat this pandemic, but in many areas of the world they are still not accessible to those who need them. Armed with learnings from the fight against HIV, we know that impact is best achieved when communities are empowered to advocate for patients to receive timely and appropriate test-and-treat services.”
Philippe Duneton, Executive Director, Unitaid said, “We now have treatment options that can prevent hospitalizations and deaths for those at high risk of developing severe or critical COVID-19. Timely deployment of adequate tests and treatments in low-resource settings, especially for the people at risk of severe cases, will be key in the response to the pandemic. And supporting civil society organisations and communities, at the heart of this endeavour, is crucial for its success.”